Al­lo­gene Over­land Bio­pharm com­pletes Shang­hai fa­cil­i­ty to man­u­fac­ture CAR-T prod­ucts

Last month, as cell ther­a­py play­er Al­lo­gene launched a study for its can­di­date tar­get­ing large B-cell lym­phoma, its joint ven­ture, Al­lo­gene Over­land Bio­pharm put the fin­ish­ing touch­es on a new CAR-T man­u­fac­tur­ing fa­cil­i­ty in Shang­hai.

In an email to End­points News, Al­lo­gene said the process from de­sign to com­ple­tion took the com­pa­ny just un­der a year, which was “tru­ly re­mark­able” giv­en that there was al­so a pe­ri­od in which Shang­hai was in lock­down as a re­sult of the Covid-19 pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER